Cipla Limited has informed the Exchange regarding 'Update on USFDA inspection at Company s manufacturing facility in Bommasandra, Bengaluru, India'.
CIPLA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
The USFDA inspected Cipla's manufacturing facility in Bommasandra, Bengaluru from 26th to 30th May 2025 under current Good Manufacturing Practices (cGMP) norms. Following this inspection, the USFDA has classified the facility as 'Voluntary Action Indicated' (VAI), as communicated via email on 4th August 2025. VAI is a relatively favourable classification, indicating that while there may be minor observations, no formal regulatory or enforcement action is required from the company. This concludes a key regulatory overhang on the Bommasandra plant, which is part of Cipla's domestic manufacturing network and contributes to its US generics business.
Positive for shareholders — the VAI classification removes near-term USFDA enforcement risk on the Bommasandra facility and allows uninterrupted production and US-market supply. It is a benign outcome and likely to be viewed as a relief by the market, though the company may still need to address minor observations voluntarily.